Risk-Based Quality in Practice
Author: Jonatan Irizarry, Founder and CEO, GlobalNEP
A practical guide to the relationships among the Quality Target Product Profile, Critical Quality Attributes, Critical Material Attributes, Critical Process Parameters, and the control strategy.
Begin with the product and the patient
Quality by Design begins with predefined objectives and emphasizes product and process understanding, process control, science, and Quality Risk Management. The terminology can appear abstract, but the relationships among the concepts are practical. They create the line of sight from the needs of the patient to the materials, process parameters, controls, data, and evidence used in manufacturing.
Quality Target Product Profile
The Quality Target Product Profile, or QTPP, is a prospective summary of the quality characteristics that the drug product should achieve, taking safety and efficacy into account. It expresses the intended product and provides a foundation for development decisions.
The QTPP is not a list of manufacturing settings. It establishes the product-level objectives from which relevant quality attributes and the eventual control strategy can be developed.
Critical Quality Attributes
A Critical Quality Attribute, or CQA, is a physical, chemical, biological, or microbiological property or characteristic that should remain within an appropriate limit, range, or distribution to ensure the desired product quality. Examples may include identity, assay, content uniformity, dissolution or release, degradation products, moisture, sterility-related characteristics, or other attributes relevant to the product.
The reason an attribute is critical should be grounded in the potential consequence to product quality and the patient. Existing controls influence the likelihood of failure and the overall risk, but they should not be used to erase the underlying significance of an attribute.
Critical Material Attributes
A Critical Material Attribute, or CMA, is a property or characteristic of an input material that should remain within an appropriate limit, range, or distribution to ensure the desired quality of the output. The relevance of a material attribute depends on the process and the CQAs it can influence.
A material attribute should not be labeled critical simply because it is measurable or included in a specification. The relationship to process performance and product quality must be understood and supported.
Critical Process Parameters
A Critical Process Parameter, or CPP, is a process parameter whose variability has an impact on a CQA and therefore should be monitored or controlled to ensure the process produces the desired quality. The important idea is the relationship: parameter variability can affect a quality attribute that matters.
Not every process parameter is critical, and not every parameter should receive the same control or data-treatment strategy. Process studies, development knowledge, manufacturing history, mechanistic understanding, and QRM help determine which relationships are meaningful.
Intermediate quality attributes
Manufacturing processes consist of connected unit operations. A quality characteristic at an intermediate step may not describe the final drug product, yet it can provide essential evidence that the process is progressing toward the required outcome. These intermediate attributes can help teams identify which material attributes and process parameters at a given step influence downstream CQAs.
The relationship is more useful than the labels
The purpose is not to create separate lists of CQAs, CMAs, and CPPs. The value comes from connecting them:
• The QTPP defines the intended product-quality objectives.
• CQAs express the properties that must be controlled to achieve the desired product quality.
• CMAs and process parameters are evaluated for their potential influence on those attributes.
• Critical parameters and material attributes inform the control strategy.
• The control strategy generates data and evidence used to monitor performance and maintain the process in a state of control.
Legacy products require knowledge reconstruction
Many established products entered commercial manufacturing before today's systematic QbD language was widely used. The relevant knowledge may be scattered across development reports, transfer documents, investigations, changes, CAPAs, validation packages, annual reviews, and the experience of long-tenured personnel.
For a legacy product, the practical challenge is to reconstruct and govern that knowledge. The organization should identify the product attributes that matter, map the unit operations, evaluate material and parameter relationships, document uncertainty, and determine whether the current control strategy reflects what has been learned.
Why this matters for data criticality
The QTPP-CQA-CMA-CPP relationship also provides a strong basis for data criticality. Data used to make or support decisions about critical attributes, parameters, materials, controls, release, and process performance deserves explicit ownership and proportionate lifecycle controls. Data should not be classified as critical solely because it originates in a regulated system; criticality should reflect its use and consequence.
Questions for a cross-functional review
• Are the CQAs current, justified, and understood outside development?
• Can the team explain which material attributes and process parameters influence each CQA?
• Where is the supporting knowledge located, and who owns it?
• Are uncertainty and conflicting evidence visible?
• Does the control strategy reflect actual process understanding and lifecycle experience?
• Have data-criticality and validation priorities been connected to these relationships?
When these connections are clear, QbD stops being a development slogan. It becomes a practical knowledge framework for control, validation, data governance, change, and continual improvement.
Related services: Quality Risk Management | Data Criticality | Regulatory Compliance Discuss your challenge
GlobalNEP helps organizations connect product and process knowledge to QRM, control strategy, data criticality, and risk-based validation - including the reconstruction of knowledge for legacy products.
